Stock market announcement archive

Minutes from Extraordinary General Meeting

May 16, 2024
The Extraordinary General Meeting of Lifecare ASA was convened as a hybrid meeting on 16 May 2024. All proposals on the agenda were adopted, cf. the notification of the Extraordinary General Meeting that was published on Oslo Stock Exchange on 2. May 2024. The complete minutes of the Extraordinary General Meeting are attached and will […]
Read more

Lifecare ASA: Updated key information relating to the preferential rights issue

May 15, 2024
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. Reference is made to the stock exchange announcement published […]
Read more

LIFE – Conversion to a public limited liability company registered

May 13, 2024
Bergen, Norway, 29 April 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that its conversion to a public limited liability company has been registered. Lifecare ASA’s conversion to a public limited liability company and corresponding name change from Lifecare AS to Lifecare ASA […]
Read more

Lifecare Q1 2024 Report – From preparations phase to pilot production

May 8, 2024
Bergen, Norway, May 5th, 2024: Today, Lifecare AS (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes Q1 financial report and operational update. Lifecare Q1 report 2024 is available here Lifecare has been delivering milestones on a continuous basis over a long period. The company has […]
Read more

Lifecare Q1 2024 report and webcast

May 7, 2024
Lifecare AS will present Q1 2024 financial and operational status in a webcast Wednesday 8 May. The webcast will be for all shareholders and interested parties at 11:00 – 11:45 CET. Lifecare’s CEO Joacim Holter presents the company’s Q1 report followed by a Q&A session where Holter will answer questions submitted in advance. Questions in […]
Read more

Extraordinary General Meeting

May 2, 2024
Lifecare AS will hold an Extraordinary General Meeting on May 16th, 2024, at 10:00 (CET). The notice with complete agenda and documents are available on https://lifecare.no/events/. It will be possible to attend the meeting in person or digitally through Orgbrain. Shareholders who wish to participate and vote at the Extraordinary General Meeting must be registered with […]
Read more

Minutes from Annual General Meeting

April 30, 2024
The Annual General Meeting of Lifecare AS was convened as a hybrid meeting on 30 April 2024. Trine Teigland (Board member) and Lutz Heinemann (Board member) were re-elected and Tone Kvåle (Board member) was elected as new member of the BoD as proposed by the Nomination Committee. No alternative candidates were proposed. All proposals on […]
Read more

LIFE – Lifecare becomes majority shareholder in RemovAid

April 29, 2024
Bergen, Norway, 29 April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), have invested NOK 2 million through a private placement in RemovAid AS, a medical technology company based in Oslo, Norway, after which Lifecare holds 81.1% of the shares in RemovAid. RemovAid has developed […]
Read more

Lifecare AS – Mandatory notification of trade

April 26, 2024
Bergen, Norway 26 April 2024: Hannibal Invest AS, a company closely associated with Hans Hekland, member of the Board of Directors of LifeCare AS (the “Company”), has on 26 April 2024 sold 150,000 shares in the Company at an average price of NOK 3.05 per share. Following this transaction, Hannibal Invest AS holds 50,000 shares […]
Read more

LIFE – Strategic investment in RemovAid AS

April 26, 2024
Bergen, Norway, 26th April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), intend to invest NOK 2 million and become the majority shareholder in RemovAid AS, a medical technology company based in Oslo, Norway. RemovAid is an ISO 13485 certified company who specializes in the […]
Read more